A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2377928
下载链接
链接失效反馈官方服务：
资源简介：
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
创建时间：
2021-06-15
